title: Early efficacy of taxotere and cisplatin chemo-radiotherapy for advanced cervical cancer.
abstract: The aim of this study was to investigate the early outcome of the taxotere and cisplatin chemoradiotherapy to the advanced cervical cancer. Fifty-six cases with cervical cancer (FIGO II b to IVa) were divided randomly into two groups: radiotherapy alone (28 cases) and radiation plus chemotherapy (TP) group. There was no difference of radiotherapy between the two groups. The RT+C cases who received TP regimen during the radiation, and DDP once weekly injection of vain, according to 20 mg/m2 and taxotere once weekly i.v. according to 35 mg/m2.These regimen were given for 4~5 weeks, and some medicine for vomiting was given to the RT+C cases. Two groups were received an oral medicine MA 160 mg every day during the treatment. The early outcome: the complete remission rate was 64.3% and partial remission rate was 35.7% in RT+C. the complete remission rate was 32.1% and partial remission rate was 39.3% in RT. The total response rate and complete remission of RT+C group was higher than that of the RT group. There was significant difference between the two groups. The taxotere and cisplatin chemoradiotherapy can improve the early outcome of the advanced cervical cancer, the adverse effects being endurable.
authors.affiliation: Department of Chemoradiotherapy, Oncology Hospital of Jingzhou, Jingzhou, China.
authors.forename: Qing-Hua
authors.initials: QH
authors.lastname: Ke
authors.forename: Shi-Qiong
authors.initials: SQ
authors.lastname: Zhou
authors.forename: Wei
authors.initials: W
authors.lastname: Du
authors.forename: Yong
authors.initials: Y
authors.lastname: Lei
authors.forename: Min
authors.initials: M
authors.lastname: Huang
authors.forename: Fei
authors.initials: F
authors.lastname: Luo
authors.forename: Ji-Yuan
authors.initials: JY
authors.lastname: Yang
mesh_terms: D000230:Adenocarcinoma / Q000556:secondary / Q000628:therapy*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001918:Brachytherapy; D002294:Carcinoma, Squamous Cell / Q000556:secondary / Q000628:therapy*; D059248:Chemoradiotherapy; D002945:Cisplatin / Q000008:administration & dosage; D000077143:Docetaxel; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D060787:Neoplasm Grading; D011379:Prognosis; D012074:Remission Induction; D043823:Taxoids / Q000008:administration & dosage; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000628:therapy*
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin